2021年中国临床肿瘤学会乳腺癌诊疗指南更新要点解读  

Chinese Society of Clinical Oncology Breast Cancer Guideline version 2021:updates and interpretations

作　　者：李健斌 江泽飞[1] Li Jianbin;Jiang Zefei(Department of Oncology medicine,PLA General Hospital,Beijing 100071,China)

机构地区：[1]解放军总医院肿瘤医学部,北京100071

出　　处：《中华医学杂志》2021年第24期1835-1838,共4页National Medical Journal of China

基　　金：首都临床特色应用研究专项(Z181100001718215)。

摘　　要：中国临床肿瘤学会乳腺癌诊疗指南自2017年颁布以来,已经完成了4版的更新,发行近30万册,获得国内外学者广泛认可。2021版指南在既往的基础上,继续秉承基于证据、兼顾可及、结合专家意见的原则进行了更新,在病理评估、新辅助治疗、辅助治疗、解救治疗、骨转移诊疗等章节进行重要更新,同时还新增药物不良反应管理、真实世界研究、生物类似药、常态化疫情防控下乳腺癌患者管理等章节,更加全面治疗乳腺癌的规范化诊疗。Objective Since the first publication in 2017,the Chinese society of clinical oncology breast cancer guidelines have been updated in four editions,and nearly 300000 volumes have been published,which has been widely recognized by scholars at home and abroad.The important updates from pathological diagnosis to therapies in the newest guideline has been updated in accordance with evidence,drug accessibility and expert opinions.Meanwhile,more chapters,like drug adverse reaction management,real-world research,biosimilar drugs,have been added,making a comprehensive guideline in guiding breast cancer standardized diagnosis and treatment.

关 键 词：乳腺癌 临床指南 更新要点 

分 类 号：R737.9[医药卫生—肿瘤]